1002347-71-8 Usage
Description
SIMVASTATIN-D6, also known as Deuterated Simvastatin, is a synthetic analog of Lovastatin and a competitive inhibitor of HMG-CoA reductase. It is a white solid and is commonly used as an internal standard for the quantification of Simvastatin by GCor LC-mass spectrometry. Due to its chemical properties, it has potential applications in various fields, particularly in the pharmaceutical industry.
Uses
Used in Pharmaceutical Industry:
SIMVASTATIN-D6 is used as an internal standard for the quantification of Simvastatin by GCor LC-mass spectrometry. This application is crucial for ensuring the accuracy and reliability of Simvastatin measurements in research and clinical settings.
Used in Antilipemic Applications:
As a competitive inhibitor of HMG-CoA reductase, SIMVASTATIN-D6 is used as an antilipemic agent. It helps in the regulation of lipid levels in the body, which can be beneficial for individuals with high cholesterol or other lipid-related conditions.
Used in Research and Development:
Due to its chemical properties and function as a competitive inhibitor, SIMVASTATIN-D6 is also used in research and development for the study of HMG-CoA reductase and its role in lipid metabolism. This can lead to the development of new drugs and therapies for various lipid-related disorders.
Check Digit Verification of cas no
The CAS Registry Mumber 1002347-71-8 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,0,2,3,4 and 7 respectively; the second part has 2 digits, 7 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 1002347-71:
(9*1)+(8*0)+(7*0)+(6*2)+(5*3)+(4*4)+(3*7)+(2*7)+(1*1)=88
88 % 10 = 8
So 1002347-71-8 is a valid CAS Registry Number.
1002347-71-8Relevant articles and documents
Synthesis of deuterium-labeled simvastatin
Tian, Lei,Tao, Jie,Chen, Liqin
, p. 625 - 628 (2011/12/03)
This study describes the synthesis of deuterium-labeled simvastatin. The stable isotope-labeled compound was prepared starting from lovastatin in nine steps with 9% overall yield.
